Syntagon Restructures to Further Improve Drug Substance Development Offering

Leading contract research provider, Syntagon, is set to implement a restructuring programme designed to further improve its offering to customers in the field of drug substance development.

Syntagon’s Sweden-based operations (Syntagon AB) will focus and strengthen its customer-oriented expertise within drug substance development, quality assurance and regulatory support, while the Group’s Latvian site (SIA Syntagon Baltic) will ramp up its capacity and know-how within the field of preclinical and clinical deliveries of drug substances.

“The reorganisation will enable Syntagon to build more dedicated core competence areas, while maintaining the high quality of service Syntagon has been delivering to its customers worldwide for the past 13 years,” says Syntagon CEO Andis Slaitas.

The reorganisation will result in the relocation of several positions from Syntagon’s Sweden base, south of the Swedish capital Stockholm, to the company’s Latvian site.

Slaitas was appointed Syntagon CEO in October this year. He has been with Syntagon since 2005 and has been instrumental in developing the Syntagon Baltic site into a world-class chemistry facility.

For further details on this press release, please contact Andis Slaitas, Syntagon CEO on andis.slaitas@syntagon.com

For more about Syntagon, visit our website at www.syntagon.com, or follow us on Twitter at http://twitter.com/Syntagon.

Tags: